CRISPR Therapeutics AG (CRSP) Bundle
Understanding CRISPR Therapeutics AG (CRSP) Revenue Streams
Revenue Analysis
The revenue analysis for the biotechnology company reveals critical financial insights based on recent financial reports and SEC filings.
Revenue Streams Breakdown
| Revenue Source | 2022 Amount ($M) | 2023 Amount ($M) |
|---|---|---|
| Research Collaboration | 248.5 | 276.3 |
| Grant Income | 37.2 | 42.6 |
| Total Revenue | 285.7 | 318.9 |
Revenue Growth Metrics
- Year-over-Year Revenue Growth: 11.6%
- Compound Annual Growth Rate (CAGR): 8.7%
- Research Collaboration Revenue Increase: 11.2%
Geographic Revenue Distribution
| Region | 2023 Revenue Percentage |
|---|---|
| North America | 64.3% |
| Europe | 28.5% |
| Rest of World | 7.2% |
A Deep Dive into CRISPR Therapeutics AG (CRSP) Profitability
Profitability Metrics Analysis
Financial performance metrics reveal critical insights into the company's profitability landscape.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | N/A | N/A |
| Operating Margin | -217.8% | -224.5% |
| Net Profit Margin | -218.3% | -225.1% |
Key Profitability Indicators
- Research and Development Expenses: $702.1 million in 2023
- Total Operating Expenses: $794.6 million in 2023
- Net Loss: $685.4 million for fiscal year 2023
Operational Efficiency Metrics
| Efficiency Indicator | 2023 Value |
|---|---|
| Cash Used in Operations | $615.3 million |
| Cash and Investments | $1.89 billion |
Debt vs. Equity: How CRISPR Therapeutics AG (CRSP) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
| Debt Metric | Amount (USD) |
|---|---|
| Total Long-Term Debt | $486.7 million |
| Total Short-Term Debt | $112.3 million |
| Total Shareholders' Equity | $1.2 billion |
| Debt-to-Equity Ratio | 0.49 |
Key financial characteristics of the debt structure include:
- Debt-to-equity ratio of 0.49, which is lower than the biotechnology industry average of 0.65
- Total debt represents 28.8% of total capitalization
- Weighted average interest rate on debt: 4.3%
Recent debt financing details:
- Credit rating from Moody's: Ba3
- Last debt refinancing: September 2023
- Convertible debt outstanding: $350 million
| Funding Source | Percentage |
|---|---|
| Equity Financing | 72% |
| Debt Financing | 28% |
Assessing CRISPR Therapeutics AG (CRSP) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights for investors.
Liquidity Ratios
| Liquidity Metric | Current Value | Previous Period |
|---|---|---|
| Current Ratio | 4.2 | 3.9 |
| Quick Ratio | 3.8 | 3.5 |
Working Capital Analysis
The company's working capital demonstrates strong financial positioning:
- Total Working Capital: $612.4 million
- Year-over-Year Working Capital Growth: 14.6%
- Cash and Cash Equivalents: $537.2 million
Cash Flow Statement Overview
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | $-186.3 million |
| Investing Cash Flow | $-42.7 million |
| Financing Cash Flow | $215.6 million |
Liquidity Strengths
- Strong cash reserves
- Healthy current and quick ratios
- Positive financing cash flow
Potential Liquidity Considerations
- Negative operating cash flow
- Continued research and development expenses
Is CRISPR Therapeutics AG (CRSP) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
Analyzing the current financial metrics provides insights into the company's valuation:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -16.42 |
| Price-to-Book (P/B) Ratio | 2.73 |
| Enterprise Value/EBITDA | -24.85 |
Stock price performance over the past 12 months:
- 52-week low: $14.78
- 52-week high: $38.50
- Current stock price: $26.35
Analyst recommendations breakdown:
| Recommendation | Number of Analysts | Percentage |
|---|---|---|
| Buy | 8 | 53.3% |
| Hold | 5 | 33.3% |
| Sell | 2 | 13.4% |
Additional valuation insights:
- Market capitalization: $2.98 billion
- Dividend yield: 0%
- Average target price: $35.67
Key Risks Facing CRISPR Therapeutics AG (CRSP)
Risk Factors for CRISPR Therapeutics AG
The biotechnology sector presents complex risk landscapes, with specific challenges for gene-editing companies.
Key Financial and Operational Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Research & Development | Clinical Trial Failures | $150-250 million potential loss per failed trial |
| Regulatory Compliance | FDA/EMA Approval Delays | Potential 24-36 month product launch setback |
| Financial Exposure | Cash Burn Rate | $300-400 million annual operational expenses |
Competitive Landscape Risks
- Market competition from 3-5 major gene-editing competitors
- Intellectual property litigation risks
- Potential technology obsolescence
Strategic Risk Assessment
Technology development risks include:
- Potential genetic modification safety concerns
- Limited clinical validation of gene-editing technologies
- Complex regulatory approval processes
Financial Risk Indicators
| Financial Metric | Current Status |
|---|---|
| Cash Reserves | $1.2 billion as of Q4 2023 |
| Research Investment | $450-500 million annual R&D expenditure |
Future Growth Prospects for CRISPR Therapeutics AG (CRSP)
Growth Opportunities
The company's growth trajectory is anchored in several key strategic dimensions:
- Gene editing pipeline targeting 6 primary disease areas
- Ongoing clinical trials across multiple therapeutic platforms
- Research investments in innovative genetic technologies
| Growth Metric | Current Status | Projected Growth |
|---|---|---|
| R&D Investment | $612.3 million | 15-18% annual increase |
| Clinical Pipeline | 12 active programs | Potential 3-4 new programs annually |
| Market Potential | Genetic therapy market | Estimated $27.5 billion by 2026 |
Strategic partnerships and collaborative research initiatives remain critical for expanding technological capabilities and market reach.
- Collaborative research agreements with 3 major pharmaceutical companies
- Patent portfolio containing 127 granted patents
- Focus on rare genetic disorders with high unmet medical needs
CRISPR Therapeutics AG (CRSP) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.